{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-000289","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.014714+00:00","generated_at":"2026-05-16T05:26:08.385272+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Silexion Therapeutics files 8-K disclosing corporate presentation for non-deal roadshow","bullets":["Filed Form 8-K on February 3, 2026, with Items 7.01 and 9.01.","Prepared a corporate presentation for use in investor meetings as part of a non-deal roadshow.","Presentation furnished as Exhibit 99.1 and incorporated by reference.","CEO Ilan Hadar signed the report on behalf of Silexion Therapeutics Corp.","Presentation titled 'Silencing Oncogenes at the Level of Gene Expression' for Nasdaq: SLXN."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-000289","json":"https://secwatch.observer/filing/0001178913-26-000289.json","markdown":"https://secwatch.observer/filing/0001178913-26-000289.md","text":"https://secwatch.observer/filing/0001178913-26-000289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000289/0001178913-26-000289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000289/zk2634285.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T05:26:08.385272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}